Hill David R, Newburg David S
Nutr Rev. 2015 Jul;73(7):463-76. doi: 10.1093/nutrit/nuv009.
Milk represents a unique resource for translational medicine: It contains a rich pool of biologically active molecules with demonstrated clinical benefits. The ongoing characterization of the mechanistic process through which milk components promote development and immunity has revealed numerous milk-derived compounds with potential applications as clinical therapies in infectious and inflammatory disease, cancer, and other conditions. Lactoferrin is an effective antimicrobial and antiviral agent in high-risk patient populations and a potentially potent adjuvant to chemotherapy in lung cancer. Enteric nutrition formulas supplemented with transforming growth factor β, a milk cytokine, have been shown to promote remission in pediatric Crohn's disease. A number of milk glycans, including human milk oligosaccharides, show promise in preclinical studies as antimicrobial and anti-inflammatory agents. While active preclinical investigations of human milk may soon result in large-scale production of human milk molecules, bovine milk components in many instances represent a practical source of bioactive milk compounds for use in clinical trials. This review summarizes current efforts to translate the compounds derived from human and bovine milk into effective clinical therapies. These efforts suggest a common pathway for the translation of milk-derived compounds into clinical applications.
它含有大量具有已证实临床益处的生物活性分子。目前对乳汁成分促进发育和免疫的机制过程的研究,已揭示出众多源自乳汁的化合物,它们在感染性和炎症性疾病、癌症及其他病症的临床治疗中具有潜在应用价值。乳铁蛋白在高危患者群体中是一种有效的抗菌和抗病毒剂,并且在肺癌化疗中可能是一种强效佐剂。添加了乳汁细胞因子转化生长因子β的肠内营养配方已被证明可促进小儿克罗恩病的缓解。包括人乳寡糖在内的多种乳汁聚糖,在临床前研究中显示出作为抗菌和抗炎剂的前景。虽然对人乳的积极临床前研究可能很快会导致人乳分子的大规模生产,但在许多情况下,牛乳成分是用于临床试验的生物活性乳汁化合物的实际来源。本综述总结了目前将源自人乳和牛乳的化合物转化为有效临床疗法的努力。这些努力为将源自乳汁的化合物转化为临床应用指明了一条共同途径。